It also asserts that GLP-1 medications do not directly affect levothyroxine absorption, a claim worth confirming with your own prescriber
The global GLP-1 receptor agonist market is projected to soar from USD 28.19 billion in 2025 to USD 63.54 billion by 2032, reflecting a compound annual growth rate of 12.3%
First approved by the FDA for type 2 diabetes, they have since altered how clinicians approach obesity treatment, swiftly changing hundreds of thousands of lives (Conley, 2025)
Preclinical Findings (Animal & Cellular) Adipose NNMT inhibition increases energy expenditure and reduces fat mass
Foundayo introduces an oral GLP-1 option, available at any time without special storage requirements
At that point, theyll be very, very cheap